Clinical Trial Update: Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ganetespib with paclitaxel, trastuzumab, and pertuzumab in metastatic HER2-positive breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Male Breast Cancer

Drugs mentioned

• Ganetespib (ganetespib)
• PACLITAXEL (PACLITAXEL)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: HER2-positive Breast Cancer, Male Breast Cancer | Phase 1 | Status: COMPLETED